Alexion Pharmaceuticals, Inc.
Early in Friday's session, traders were abuzz with news that Alexion had cancelled out of a Credit Suisse conference. Taken as a sign that the company might have big news it wasn't ready to reveal, the street seemed to be thinking acquisition was in the air. This sentiment was only bolstered by a Citi Research note on Alexion citing a $175 price target.
Things changed just after noon when Benzinga broke the news that an analyst from Leerink suggested Alexion Pharma could be
Shares of Alexion were trading down 1.69 percent at $125.36 in early afternoon trading.
Benzinga contacted Alexion for comment and the company responded, "[We continue] to finalize our 10-Q in accordance with our internal processes."
Editor Note, November 4, 4:10 p.m. EST: Alexion's response was added post-initial publication to reflect the most recent correspondence between Alexion and Benzinga.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.